Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap
Small Science · 2026-05 · 6 (5)
DOI: 10.1002/smsc.70294 ↗Kurz gefasst
Editorial in der Zeitschrift Small Science, online erschienen am 11.05.2026. Verfasst von Hamdi Al-Azzani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xiangya School of Pharmaceutical Sciences Central South University Changsha China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The escalating burden of musculoskeletal disorders, such as osteoarthritis, osteoporosis, inflammatory arthritis, bone tumors, and skeletal infections, necessitates precisely targeted therapeutics beyond conventional interventions. Nucleic acid aptamers are a next‐generation ligand class distinguished by their high affinity, target specificity, low immunogenicity, and programable chemical properties. Their incorporation into nanoparticles, DNA nanostructures, hydrogels, microneedles, exosomes, and implant coatings is reshaping the therapeutic landscape of bone and joint diseases. This review synthesizes preclinical evidence from in vivo and ex vivo models, highlighting aptamer‐functionalized carriers for targeting bone resorption, cartilage damage, synovial inflammation, bacterial infections, and skeletal malignancies. A classification framework based on aptamer target types, including cellular, extracellular matrix, signaling pathway, and pathogen‐specific ligands, is mapped to appropriate nanocarriers and delivery routes. Key engineering parameters, including dissociation constant, ligand density, multivalency, linker design, particle size, and surface charge, are critical determinants of biodistribution, tissue penetration, and target specificity. Bone‐to‐reticuloendothelial system ratio and joint tissue retention metrics were proposed to guide rational design. Safety profiles, immunogenicity, and manufacturing feasibility were integrated into a translational roadmap. Standardized reporting protocols and priority indications, including intraarticular delivery in arthritis, bone defect regeneration, and targeted delivery in bone malignancies, have been identified to facilitate clinical translation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Xiangya School of Pharmaceutical Sciences Central South University Changsha China.
- Department of Orthopedics Xiangya Hospital Central South University Changsha China.
- National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha China.
- Department of Microbiology School of Basic Medical Sciences Central South University Changsha China.
- Department Orthopedic Xiangya Third Hospital Changsha China.
- Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations School of Pharmaceutical Science Changsha Medical University Changsha China.
ORCID-Profile: Djandan Tadum Arthur Vithran, Wenhu Zhou, Xiaoqiang Mao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Al-Azzani, H., Vithran, D. T. A., Batool, S. S., Alshabi, M. M. A., Zhou, W., & Mao, X. (2026). Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap. Small Science, 6(5). https://doi.org/10.1002/smsc.70294
Vancouver
Al-Azzani H, Vithran DTA, Batool SS, Alshabi MMA, Zhou W, Mao X. Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap. Small Science. 2026;6(5). doi:10.1002/smsc.70294
BibTeX
@article{AlAzzani2026,
author = {Al-Azzani, Hamdi and Vithran, Djandan Tadum Arthur and Batool, Syeda Sundas and Alshabi, Malek Mohammed Ali and Zhou, Wenhu and Mao, Xiaoqiang},
title = {Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap},
journal = {Small Science},
year = {2026},
volume = {6},
number = {5},
doi = {10.1002/smsc.70294}
}
EUVIMED